Amalgamated Bank Sells 489 Shares of Cencora, Inc. (NYSE:COR)

Amalgamated Bank decreased its position in Cencora, Inc. (NYSE:COR) by 1.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 35,741 shares of the company’s stock after selling 489 shares during the period. Amalgamated Bank’s holdings in Cencora were worth $8,052,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Rise Advisors LLC bought a new stake in Cencora in the 1st quarter worth $25,000. New Millennium Group LLC bought a new stake in shares of Cencora in the second quarter worth about $26,000. Legacy Bridge LLC purchased a new position in Cencora during the 1st quarter valued at about $27,000. TCTC Holdings LLC bought a new position in Cencora during the 1st quarter valued at approximately $29,000. Finally, TFO Wealth Partners LLC purchased a new stake in Cencora in the 1st quarter worth approximately $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Price Performance

Shares of NYSE COR opened at $226.56 on Friday. The company has a 50 day simple moving average of $234.73 and a two-hundred day simple moving average of $233.18. Cencora, Inc. has a fifty-two week low of $178.21 and a fifty-two week high of $247.66. The company has a market capitalization of $45.19 billion, a price-to-earnings ratio of 24.79, a P/E/G ratio of 1.55 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. During the same quarter last year, the company earned $2.92 EPS. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. Analysts expect that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date was Friday, August 9th. Cencora’s payout ratio is 22.32%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on COR shares. Leerink Partners reissued an “outperform” rating and set a $275.00 target price on shares of Cencora in a research note on Thursday, June 27th. Bank of America reissued a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company boosted their price target on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Finally, Robert W. Baird lowered their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and an average price target of $256.67.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.